Revenue decline in the pharmaceutical field due to lower customer trial volumes and fewer CRO orders
First written in FY2023-Q1. 5 of 13 entries say "Reframed", first in FY2024-Q1. Latest entry: 2026-08-07.
No other company in this theme has enough history to compare yet.
- FY2026-H1MitigatedAnnual report
「In the Pharmaceutical division, increased orders from certain major customers among foreign-affiliated pharmaceutical companies and growth in orders from CROs (contract research organizations) contributed to a 5.0% year-on-year increase in revenue to ¥1,284 million.」
Orders from CROs, which had previously been declining, grew, while orders from major customers among foreign-affiliated pharmaceutical companies also increased, bringing the Pharmaceutical division back to revenue growth. - FY2025-H1ReframedAnnual report
「In the Pharmaceutical division, the company worked to build ongoing relationships with customers and expand its customer base to capture demand. Orders from domestic pharmaceutical companies and CROs (contract research organizations) increased year on year, but weak orders from foreign-affiliated pharmaceutical companies affected results. Revenue decreased 0.8% year on year to ¥1,222 million.」
The explanation shifted from a primary focus on trial-schedule factors to divergence by customer type, with increased orders from domestic pharmaceutical companies and CROs and weak orders from foreign-affiliated pharmaceutical companies. - FY2024ReframedAnnual report
「In the Pharmaceutical division, the company worked to strengthen relationships with customers to expand orders for documents related to new drug development. However, orders from domestic pharmaceutical companies remained nearly flat year on year, while lower orders from foreign-affiliated pharmaceutical companies, foreign-affiliated CROs (contract research organizations) and medical device companies also affected results. Revenue decreased 6.8% year on year to ¥2,605 million.」
The explanation became more specific, shifting from a primary focus on trial-schedule factors to divergence by customer type, with orders from domestic pharmaceutical companies nearly flat and orders from foreign-affiliated pharmaceutical companies, foreign-affiliated CROs and medical device companies declining. - FY2024-Q3ReframedAnnual report
「In the Pharmaceutical division, orders from foreign-affiliated pharmaceutical companies remained nearly flat year on year, but lower orders from domestic pharmaceutical companies and foreign-affiliated CROs (contract research organizations) affected results. Revenue decreased 8.3% year on year to ¥1,870 million.」
The explanation of the factors behind the decline in Pharmaceutical revenue shifted from lower demand due to trial schedules to divergence by customer type, with foreign-affiliated pharmaceutical companies nearly flat and orders from domestic pharmaceutical companies and foreign-affiliated CROs declining. - FY2024-Q2ReframedAnnual report
「In the Pharmaceutical division, orders from domestic pharmaceutical companies were on a recovery trend due to increased orders from several customers. However, lower orders from foreign-affiliated pharmaceutical companies and foreign-affiliated CROs (contract research organizations) affected results, and revenue decreased 8.7% year on year to ¥1,232 million.」
The explanation shifted from the previous focus on lower demand due to customers’ trial schedules to divergence by customer type, with recovery among domestic pharmaceutical companies and lower orders from foreign-affiliated pharmaceutical companies and foreign-affiliated CROs. - FY2024-Q1ReframedAnnual report
「In the Pharmaceutical division, orders from foreign-affiliated pharmaceutical companies remained firm, but domestic pharmaceutical companies remained weak, while lower orders from CROs (contract research organizations) also affected results. Revenue decreased 5.4% year on year to ¥618 million.」
Although lower CRO orders continued, the company specifically cited weakness among domestic pharmaceutical companies in addition to the previous trial-schedule factor, while orders from foreign-affiliated pharmaceutical companies remained firm, showing divergence by customer type. - FY2023RestatedAnnual report
「In the Pharmaceutical division, translation demand remained weak due to customers’ trial schedules. Lower orders from CROs (contract research organizations), together with a decline following the decrease in infectious-disease-related projects received in the previous fiscal year, also affected results. Revenue decreased 3.7% year on year to ¥2,796 million.」
Customers’ trial schedules, lower CRO orders and a decline following infectious-disease-related projects all contributed to the full-year decline in Pharmaceutical revenue. - FY2023-Q3RestatedAnnual report
「In the Pharmaceutical division, translation demand remained weak due to customers’ trial schedules. Lower orders from CROs (contract research organizations), together with a decline following the decrease in infectious-disease-related projects received in the previous fiscal year, also affected results. Revenue decreased 6.1% year on year to ¥2,041 million.」
Weak demand due to customers’ trial schedules and lower CRO orders continued, while a decline following the previous fiscal year’s infectious-disease-related projects also contributed to the decline in Pharmaceutical revenue. - FY2023-Q2RestatedAnnual report
「In the Pharmaceutical division, translation demand temporarily declined due to customers’ trial schedules. Lower orders from CROs (contract research organizations), together with a decline following the decrease in infectious-disease-related projects received in the previous fiscal year, also affected results. Revenue decreased 6.7% year on year to ¥1,350 million.」
Temporary demand weakness caused by customers’ trial schedules and lower CRO orders continued, while a decline following the previous fiscal year’s infectious-disease-related projects also contributed to the decline in Pharmaceutical revenue. - FY2023-Q1MaterialisedAnnual report
「In the Pharmaceutical division, translation demand temporarily declined due to customers’ trial schedules, while lower orders from CROs (contract research organizations) also affected results. Revenue decreased 8.5% year on year to ¥654 million.」
Temporary demand weakness caused by customers’ trial schedules and lower CRO orders resulted in an 8.5% year-on-year decline in Pharmaceutical revenue.